Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy
- 4 April 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 20 (6), 863-870
- https://doi.org/10.1097/01.aids.0000218550.85081.59
Abstract
Little is known about the prevalence and pattern of hepatitis B virus (HBV) mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy. HBV polymerase/envelope/basal core promoter/pre-core sequences from 81 HIV-HBV co-infected persons who received at least 6 months 3TC were compared to HBV reference sequences. Host and viral characteristics associated with HBV mutations were determined. HBV viraemia was detected in 53 persons (65%) and was associated with lower CD4 cell count nadir and higher HIV RNA at the time of testing but not with 3TC duration. Known 3TC-resistant mutations occurred in 50% and 94% of viremic patients with < 2 years and > 4 years 3TC, respectively. The CD4 cell count at testing was significantly higher in those with 3TC-resistant mutations. The triple polymerase mutant (rtL173V, rtL180M, rtM204V), which behaves as a vaccine escape mutant in vitro, occurred in 17% of viraemic patients. Polymerase mutations that may confer resistance to other anti-HBV agents were also detected. In HIV-HBV co-infected patients, greater immunocompromise is associated with continued HBV viraemia while on 3TC, and development of 3TC-resistant mutations are inevitable with prolonged 3TC use. These mutant viruses may limit future therapeutic options due to cross-resistance or may produce HBV vaccine escape mutants. Thus, timing and selection of antiretroviral therapy is critical in this population.This publication has 34 references indexed in Scilit:
- Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to LamivudineAntimicrobial Agents and Chemotherapy, 2004
- HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapyHIV Medicine, 2003
- The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count)AIDS, 2003
- Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV–HBV co-infected individualsAIDS, 2003
- Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus–Coinfected Persons in a Randomized, Controlled Study (CAESAR)The Journal of Infectious Diseases, 1999
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Hepatitis B and C in HIV-infected patients: Prevalence and prognostic valueJournal of Hepatology, 1997
- Interactions between HIV and hepatitis B virus in homosexual menAIDS, 1997
- The Influence of Human Immunodeficiency Virus Type 1 Infection on the Development of the Hepatitis B Virus Carrier StateThe Journal of Infectious Diseases, 1991
- THE MULTICENTER AIDS COHORT STUDY: RATIONALE, ORGANIZATION, AND SELECTED CHARACTERISTICS OF THE PARTICIPANTSAmerican Journal of Epidemiology, 1987